Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial
复制标题
阿扎胞苷 5 天和 7 天给药治疗骨髓增生异常综合征的前瞻性比较:JALSG MDS212 试验
DOI:
10.1007/s12185-022-03347-3
复制
发表时间:
2022
影响因子:
2.1
通讯作者:
Ohtake S
中科院分区:
文献类型:
--
作者:
Miyazaki Y;Kiguchi T;Sato S;Usuki K;Ishiyama K;Ito Y;Suzuki T;Taguchi J;Chiba S;Dobashi N;Tomita A;Harada H;Handa H;Horiike S;Maeda T;Matsuda M;Ichikawa M;Hata T;Honda S;Iyama S;Suzushima H;Moriuchi Y;Kurokawa T;Yokota K;Ohtake S
A 7-day azacitidine treatment schedule significantly delayed the time to leukemia in patients with higher-risk myelodysplastic syndromes (MDS) compared with a 5-day treatment schedule. These findings were published in the International Journal of Hematology.A phase 3 head-to-head trial of 7-day azacitidine (AZA-7) and a 5-day azacitidine (AZA-5) treatment schedules found a trend for AZA-7 to improve survival. In this analysis, data from the JALSG MDS212 study were reviewed for evidence of an effect on delaying transformation to leukemia.
登录
查看更多内容
影响因子:
3.5
作者:
E. Scalzulli;Matteo Molica;Danilo Alunni Fegatelli;G. Colafigli;L. Rizzo;M. Mancini;F. Efficace;R. Latagliata;R. Foà;M. Breccia
通讯作者:
M. Breccia
影响因子:
2.7
作者:
Garcia-Delgado, Regina;de Miguel, Dunia;Sanz, Guillermo
通讯作者:
Sanz, Guillermo
影响因子:
12.8
作者:
Martin, Mike G.;Walgren, Richard A.;Vij, Ravi
通讯作者:
Vij, Ravi
影响因子:
51.1
作者:
Fenaux, Pierre;Mufti, Ghulam J.;Hellstrom-Lindberg, Eva;Santini, Valeria;Finelli, Carlo;Giagounidis, Aristoteles;Schoch, Robert;Gattermann, Norbert;Sanz, Guillermo;List, Alan;Gore, Steven D.;Seymour, John F.;Bennett, John M.;Byrd, John;Backstrom, Jay;Zimmerman, Linda;McKenzie, David;Beach, C. L.;Silverman, Lewis R.
通讯作者:
Silverman, Lewis R.
影响因子:
45.3
作者:
Silverman, LR;Demakos, EP;Holland, JF
通讯作者:
Holland, JF